Pilot safety study of liposomal prostaglandin (PGE1) in respiratory exacerbations in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 1, Issue 2, 2002, Pages 90-93

  Taylor, C J ^a   McGaw, J ^a   Rigby, A S ^a   Threlfall, D ^a   Karmel, J ^b  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^b Liposome Company   (United Kingdom)

Author keywords

Cystic fibrosis; Liposomal prostaglandin

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; IBUPROFEN; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; LIPOPROSTAGLANDIN E1; LIPOSOME; PHOSPHATIDYLCHOLINE; PLACEBO; PREDNISONE; PROSTAGLANDIN E1;

ACUTE RESPIRATORY TRACT DISEASE; ADOLESCENT; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG INFUSION; DRUG SAFETY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASE; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; METHODOLOGY; MULTICENTER STUDY; OUTCOMES RESEARCH; PILOT STUDY; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SPUTUM; SPUTUM LEVEL; TREATMENT OUTCOME;

ADOLESCENT; ALPROSTADIL; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; LUNG DISEASES; PHOSPHATIDYLCHOLINES; PILOT PROJECTS; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; SPUTUM; TREATMENT OUTCOME;

EID: 0036299623     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-1993(02)00034-6     Document Type: Article

References (19)

1. Incidence, population and survival of cystic fibrosis patients in the UK. 1968-95
2. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonisation with Pseudomonas aeruginosa
3. Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology
4. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis
5. Alternate day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis
6. Effect of high-dose i ibuprofen in patients with cystic fibrosis
7. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis
8. Proteolytic inactivation of alpha1 proteinase inhibitor in infected bronchial secretions from patients with cystic fibrosis
9. Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: Effects of antimicrobial treatment against Pseudomonas aeruginosa
10. Lung injury induced by leukocyte proteases
11. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis
12. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line
13. 1 administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model
14. Liposome-entrapped PGE1 posttreatment decreases IL-1α-induced neutrophil accumulation and lung leak in rats
15. Endogenously opsonised particles divert prostanoid action from lethal to protective in models of experimental endotoxemia
16. Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosis
17. 1 in acute respiratory distress syndrome: A placebo-controlled, randomised, double-blind, multicenter clinical trial
18. Interleukin-8: An important chemoattractant in sputum of patients with chronic inflammatory airway diseases
19. Statistical methods in epidemiology. II. A commonsense approach to sample size estimation